Vijaya Diagnostic enters Guwahati with a profitable base

Vijaya Diagnostic Centre has built its brand on a simple promise: dependable diagnostics delivered at scale. On September 11, 2026, the company outlined its next geographic step through the planned 100 percent acquisition of the integrated diagnostic business undertaking of Arya Wellness Centre in Guwahati, Assam. The transaction is being executed via a Business Transfer Agreement on a slump sale basis, with an indicated consideration of about ₹46 crore, funded through internal accruals.

What stands out is that this is not a greenfield entry. Arya Wellness Centre comes with an operating history, a single well equipped centre on GS Road in Guwahati supported by a central reference laboratory, and a financial profile that is already profitable. For FY26, the business reported revenue from operations of ₹260 million, EBITDA of ₹56 million at a 21.4 percent margin, and adjusted PAT of ₹25 million at a 9.5 percent margin. Vijaya’s framing is direct: the deal is expected to be EPS accretive from the onset, while still fitting its capital efficiency and return thresholds.

The acquisition also has a strategic context. Vijaya positions Guwahati as a natural extension of its growing presence in West Bengal and as a gateway to the broader North East region. Post acquisition, the network count in the presentation moves from 6 states and 166 centres to 7 states and 167 centres.

The asset being acquired and why it matters

Arya Wellness Centre is described as a leading B2C focused integrated diagnostic centre in Guwahati serving the North East market. It was founded in 2021 as a joint venture or association of persons between North Eastern Medical Research Institute Limited, which operates Arya Hospital, and Hexagonal Research Private Limited, representing a group of reputed doctors. The centre is strategically located on GS Road, positioned by the presentation as Guwahati’s key healthcare hub.

The mix of services explains the positioning. The business split by category is shown as advanced radiology at 35 percent, basic radiology at 9 percent, advanced pathology at 16 percent, and basic pathology at 40 percent. In other words, it is not an imaging only story or a lab only story. It is an integrated platform with meaningful exposure to both advanced and routine work. The key metrics reinforce this balance: radiology contributes 44 percent and pathology 56 percent. Daily footfalls are shown as 200 plus. Home collection is 7 percent.

This matters because the North East is not being approached as a long incubation market in this transaction. Vijaya is buying an asset with a built out set of modalities, including MRI, CT scan, ultrasound, neurology, cardiology, gastro, X ray, mammogram, endoscopy, and laboratory. The breadth supports cross selling and repeat use, which is important for a B2C heavy model.

The other anchor is clinician pedigree. The presentation highlights that 85 percent plus of the business comes from B2C, attributed to strong pedigree of doctors in pathology and radiology. Promoters include Dr. Bijoya Goswami of NEMRIL, founder and managing director of Arya Hospital with 40 plus years of entrepreneurial experience, along with several doctors from HRPL with 20 plus years of experience across pathology, radiology, and interventional radiology.

Deal structure, valuation signals, and closing timeline

The transaction consideration is stated at about ₹46 crore for a 100 percent business acquisition via a slump sale. The valuation is shown as about 8 to 9 times adjusted FY26 Ind AS EBITDA. Consideration is to be funded through internal accruals.

A multiple in this range, on a profitable base business, is a useful signal even without further detail on asset life, equipment condition, or lease terms, none of which are provided in the presentation. It indicates that Vijaya is trying to keep its entry valuation disciplined rather than paying for blue sky projections. That discipline is consistent with the presentation’s explicit line that the deal maintains focus on capital efficiency and return thresholds.

Timelines are also clearly framed as indicative. The BTA was signed on 10 Sep 2026 and the transaction was announced around that period. Closing is targeted for about Nov or Dec 2026, subject to satisfaction or waiver of conditions precedent, transition, and completion requirements. This structure matters because healthcare service acquisitions often fail to create value when integration drifts. The use of conditions precedent, a formal transition phase, and an operational handover suggests the company is prioritizing execution sequencing.

Financial summary from the presentation

Strategic fit: East India continuity and a North East gateway

Vijaya’s stated rationale is not just about adding one more pin on the map. It positions Guwahati as a natural extension to its growing presence in West Bengal and an attractive gateway to the wider North East. That framing implies that management sees patient flows, referral patterns, or brand expansion routes that connect eastern markets.

The asset offers immediate access to infrastructure and clinical capabilities, which is the key difference versus building from scratch. In diagnostics, time to scale is not only about setting up equipment. It is also about clinician relationships, local recall, and patient trust. Arya Wellness Centre is described as having a recognized local presence and a strong B2C base driven by reputed clinicians.

The service line emphasis also supports Vijaya’s integrated model. The presentation explicitly calls out high end imaging, interventional procedures, and histopathology work. In many diagnostic businesses, advanced modalities can improve contribution per patient, while basic pathology can stabilize volumes and drive repeat usage. Arya’s mix shows both. The category mix suggests the platform is not over dependent on one modality, which can reduce earnings volatility when pricing or volume in a single line changes.

Financially, the presentation points to healthy economics, including about 80 percent gross margin and about 21 percent EBITDA margin. The report provides the EBITDA margin but not the gross margin computation, so investors should treat the gross margin statement as directional rather than something that can be reconciled from the slide. Still, the EBITDA margin in the low 20s on ₹260 million of revenue suggests the business is not in a ramp up phase, and that operating leverage is already visible.

Network expansion snapshot

Management tone: quality, patient experience, and calibrated expansion

Management commentary in the presentation puts emphasis on quality and patient experience, alongside geographic logic. The Managing Director and CEO, Ms. Suprit Reddy, describes the entry into Guwahati as an important milestone in building a high quality integrated diagnostics platform. The quote ties the move to the company’s growing presence in West Bengal and repeats the gateway to the North East idea.

The commentary also addresses the cultural fit of the acquired asset. Arya Wellness Centre is described as being built on an ethos aligned with Vijaya’s philosophy of high quality diagnostics with a focus on patient experience and convenience. This is important because integration risk in healthcare is often cultural rather than technical. If patient experience standards differ, the acquirer can lose volumes before it gets the benefits of procurement or back end integration.

Finally, management signals a phased growth plan. The presentation says the acquisition provides a strong platform to establish a meaningful presence in Assam and progressively expand across the North Eastern region, and that over time the company intends to build upon this base through a calibrated expansion strategy. The word calibrated is worth noting. It indicates that the company is not committing to an aggressive rollout timetable in a region where it may still be learning market micro dynamics.

What investors should watch from here

The deal, as presented, is a straightforward entry into a new region through an already profitable and B2C oriented asset. The purchase consideration of about ₹46 crore, at about 8 to 9 times adjusted FY26 EBITDA, is positioned as EPS accretive from the start. The closing is targeted for Nov or Dec 2026, subject to conditions precedent and handover steps.

The next set of questions are execution focused. First is transition quality. The acquired platform is clinician led and B2C heavy, so continuity of clinical leadership and patient experience will matter more than rapid standardization. Second is whether Vijaya can use the Guwahati base to build a broader North East presence without diluting returns. The presentation offers the strategic intent, but the pace and format of expansion are not detailed.

Third is how the integrated mix evolves. Arya currently shows a near balanced split between radiology and pathology, with a sizable share in basic pathology and advanced radiology. If Vijaya can preserve this balance while scaling volumes, it can keep the unit economics stable. If mix shifts sharply toward one side, margins and capex needs could change.

Investor takeaways

This presentation is about strategic clarity with disciplined execution signals. Vijaya is entering the North East through Guwahati, using an established single site platform with a central reference lab and a profitable FY26 profile. The economics shared in the slides indicate a mature base business, not a turnaround.

If the company closes the transaction within the indicated Nov to Dec 2026 window and manages the handover without disrupting the clinician driven B2C engine, it will have a credible starting point in Assam. From there, value creation will depend on how carefully it expands across the North East while holding to the same capital efficiency and return thresholds that management highlights in the transaction framing.